Clinical Trials Browser

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03870750 2026-01-12

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Phase 2/3 Terminated

458 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Phase 2/3 Terminated

18 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05694013 2025-10-22

ORIGAMA

Phase 2/3 Terminated

49 enrolled 14 charts

Tumor-Agnostic

Neoplasms

NCT05130866 2025-10-07

POPLAR-NF2

Phase 2/3 Terminated

25 enrolled

CNS

Neurofibromatosis 2

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

600 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Phase 2/3 Terminated

20 enrolled 18 charts

Dermatologic

Melanoma

NCT05149807 2025-08-20

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Phase 2/3 Terminated

81 enrolled

Gastrointestinal

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Phase 2/3 Terminated

5 enrolled

Gynecologic

Endometrial Neoplasms

NCT04159155 2025-08-12

CAN-STAMP

Phase 2/3 Terminated

11 enrolled

Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05269355 2025-06-13

SUNRISELMS

Phase 2/3 Terminated

359 enrolled 15 charts

Sarcoma

Leiomyosarcoma

NCT00518869 2025-06-04

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

Phase 2/3 Terminated

13 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Fatigue

NCT04856787 2025-05-18

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Phase 2/3 Terminated

62 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT02807181 2025-05-09

SIRCCA

Phase 2/3 Terminated

89 enrolled 23 charts

Gastrointestinal

Cholangiocarcinoma

NCT06281106 2025-04-02

TYPP

Phase 2/3 Terminated

2 enrolled

Psoriasis

NCT02641639 2025-03-24

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Phase 2/3 Terminated

70 enrolled 16 charts

Gynecologic

Platinum Resistant Ovarian Cancer

Clinical Trials

SPARK-ALL: Calaspargase Pegol in Adults With ALL

Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

ORIGAMA

POPLAR-NF2

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

CAN-STAMP

SUNRISELMS

Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

SIRCCA

TYPP

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer